Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren’s Syndrome Dry Eye

References

• Moutsopoulos HM, Chused TM, Mann DL, et al. Sjogren’s syndrome (Sicca syndrome): current issues. Ann Intern Med. 1980;92(2 Pt 1):212–226.
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workShop (2007). Ocul Surf. 2007;5(2):75–92.
   PubMed Web of Science ®Google Scholar
• Raphael M, Bellefqih S, Piette JC, Le Hoang P, Debre P, Chomette G. Conjunctival biopsy in Sjogren’s syndrome: correlations between histological and immunohistochemical features. Histopathology. 1988;13:191–202.
   PubMed Web of Science ®Google Scholar
• Hikichi T, Yoshida A, Tsubota K. Lymphocytic infiltration of the conjunctiva and the salivary gland in Sjogren’s syndrome. Arch Ophthalmol. 1993;111:21–22.
   PubMedGoogle Scholar
• Pflugfelder SC, Huang AJ, Feuer W, Chuchovski PT, Pereira IC, Tseng SC. Conjunctival cytologic features of primary Sjogren’s syndrome. Ophthalmology. 1990;97:985–991.
   PubMed Web of Science ®Google Scholar
• Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in Sjogren syndrome dry eye patients and non-Sjogren syndrome dry eye patients. Am J Ophthalmol. 2013;156(2):247–253, e241. doi:10.1016/j.ajo.2013.04.003.
   PubMed Web of Science ®Google Scholar
• Aragona P, Aguennouz M, Rania L, et al. Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmology. 2015;122(1):62–71. doi:10.1016/j.ophtha.2014.07.048.
   PubMed Web of Science ®Google Scholar
• Liu R, Gao C, Chen H, Li Y, Jin Y, Qi H. Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease. PLoS One. 2017;12(4):e0173301. doi:10.1371/journal.pone.0173301.
   PubMed Web of Science ®Google Scholar
• Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26(4):431–437. doi:10.1097/ICO.0b013e31803dcda2.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren’s syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201–211.
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–2292.
   PubMed Web of Science ®Google Scholar
• Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–651.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Wilhelmus KR, Osato MS, Matoba AY, Font RL. The autoimmune nature of aqueous tear deficiency. Ophthalmology. 1986;93:1513–1517.
   PubMed Web of Science ®Google Scholar
• Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829–836.
   PubMedGoogle Scholar
• Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:37–42. doi:10.4137/OED.S16067.
   PubMedGoogle Scholar
• Byun YS, Rho CR, Cho K, Choi JA, Na KS, Joo CK. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study. Korean J Ophthalmol. 2011;25(6):369–374. doi:10.3341/kjo.2011.25.6.369.
   PubMedGoogle Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A phase 2 study group. Ophthalmology. 2000;107:967–974.
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% Cyclosporine eye drops in the treatment of dry eye syndrome: A systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–225. doi:10.1016/j.jtos.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000;107:631–639.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28. doi:10.1016/j.ejpb.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2:238–257.
   PubMedGoogle Scholar
• Kim HS, Kim TI, Kim JH, et al. Evaluation of clinical efficacy and safety of a novel Cyclosporin A nanoemulsion in the treatment of dry eye syndrome. J Ocul Pharmacol Ther. 2017;33(7):530–538. doi:10.1089/jop.2016.0164.
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, et al. American college of rheumatology classification criteria for sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s international collaborative clinical alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475–487.
   PubMed Web of Science ®Google Scholar
• Delaleu N, Jonsson MV, Appel S, Jonsson R. New concepts in the pathogenesis of Sjogren’s syndrome. Rheum Dis Clin North Am. 2008;34(4):833–845, vii. doi:10.1016/j.rdc.2008.08.004.
   PubMed Web of Science ®Google Scholar
• Hwang J, Chung SH, Jeon S, Kwok SK, Park SH, Kim MS. Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary Sjogren syndrome. Cornea. 2014;33(7):663–667. doi:10.1097/ICO.0000000000000147.
   PubMed Web of Science ®Google Scholar
• Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren’s syndrome international registry. Am J Ophthalmol. 2010;149(3):405–415. doi:10.1016/j.ajo.2009.09.013.
   PubMed Web of Science ®Google Scholar
• Tseng SC. Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology. 1985;92:728–733.
   PubMed Web of Science ®Google Scholar
• Singh R, Joseph A, Umapathy T, Tint NL, Dua HS. Impression cytology of the ocular surface. Br J Ophthalmol. 2005;89(12):1655–1659. doi:10.1136/bjo.2005.073916.
   PubMed Web of Science ®Google Scholar
• Nelson JD. Impression cytology. Cornea. 1988;7:71–81.
   PubMed Web of Science ®Google Scholar
• Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol. 1983;101:1869–1872.
   PubMed Web of Science ®Google Scholar
• Anshu, Munshi MM, Sathe V, Ganar A. Conjunctival impression cytology in contact lens wearers. Cytopathology. 2001;12:314–320.
   PubMed Web of Science ®Google Scholar
• Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. 2010;91(4):524–529. doi:10.1016/j.exer.2010.07.008.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 2011;27(1):23–27. doi:10.1089/jop.2010.0085.
   PubMed Web of Science ®Google Scholar
• Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci. 2012;53(4):2292–2299. doi:10.1167/iovs.11-8829.
   PubMed Web of Science ®Google Scholar
• Zhou XQ, Wei RL. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea. 2014;33(7):760–767. doi:10.1097/ICO.0000000000000123.
   PubMed Web of Science ®Google Scholar
• Straub M, Bron AM, Muselier-Mathieu A, Creuzot-Garcher C. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. Br J Ophthalmol. 2016;100(11):1547–1550. doi:10.1136/bjophthalmol-2015-306930.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–337.
   PubMed Web of Science ®Google Scholar
• Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492–496.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Effect of cyclosporine ophthalmic emulsion on the number of inflammatory cells and goblet cells in conjunctival biopsies of patients with dry eye. Invest Ophth Vis Sci. 1999;40:S771–S771.
   Web of Science ®Google Scholar
• Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50(7):3203–3209. doi:10.1167/iovs.08-2476.
   PubMed Web of Science ®Google Scholar